<DOC>
	<DOCNO>NCT00638950</DOCNO>
	<brief_summary>The effect n-3 LC-PUFA-supplemented dairy product inflammation immunological parameter , biomarkers oxidative stress , serum lipid , disease activity determine patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Recent study suggest n-3 LC-PUFA may improve cardiovascular inflammatory disease . As precondition participate study , subject provide information write verbally detail study . Informed consent obtain volunteer . Before begin study , participant subject medical examination Clinic Rheumatology ( Internal Medicine III , Friedrich Schiller University , Jena ) . The RA diagnose accord 1987 revised criterion American Rheumatism Association ( ARA ) . Severity disease activity evaluate use disease activity score DAS 28 . Forty five subject ( 43 f , 2 ) randomly divide two group carry double-blind , placebo-controlled cross-over study . The study consist two investigation period 12 week , eight-week washout period . Patients receive 40 g fat daily ( 200 g yoghurt 3.8 % fat , 30 g cheese 50 % fat dry matter , 20-30 g butter ) . The milk fat partially exchange special oil high amount eicosapentaenoic acid ( EPA ) , docosahexaenoic acid ( DHA ) , alpha linoleic acid ( ALA ) . The daily dose n-3 FA amount 2.4 g , consist 1.1 g ALA , 0.7 g EPA , 0.1 g DPA , 0.4 g DHA . The placebo product commercial dairy product comparable fat content . Venous blood 24h urine collect begin end period . The DAS 28 score assess begin end period , respectively .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Clear diagnosis Rheumatoid Arthritis Patients receive nonsteroidal antiinflammatory drug ( NSAID ) corticosteroid ( max . 15 mg/d ) eligible dosage stable least 4 week day 1 study remain limit throughout study Patients diseasemodifying antirheumatic drug ( DMARD ) constant dosage least 8 week throughout study Subjects gastrointestinal metabolic disease , alcohol abuse , take dietary supplement ( e. g. fish oil capsule ) , know allergy foodstuff indigestibility patient 's request , serious infection , inadequate control arthritis symptom ( 50 % increase number swollen tender joint ) , reinstitution therapy DMARD , patient compliance study protocol doubtful .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>n-3 LC-PUFA</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>disease activity</keyword>
	<keyword>inflammation</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>immune system</keyword>
</DOC>